Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for blood pressure variability and LV mass index in type 2 diabetes with hypertension
ChiCTR2000040103Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Anhui Medical University
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of empagliflozin in type 2 diabetes mellitus (T2DM) and hypertension (HTN) (2 arms), sponsored by The Second Affiliated Hospital of Anhui Medical University. Primary endpoints: Blood pressure variability and Left ventricular mass index. Planned start Dec 2020; status: not yet recruiting.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)hypertension (HTN)
Beyond the preview
Go deeper on ChiCTR2000040103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040103.